.You wont get any responses that deal in reality.Good post.
.Iplex proved ( company's words) "no more effective than a sugar pill" There is no interest in iplex beyond ROP.
.The only ones believing iplex hype are a fewclowns here. Investors have moved on. To INSM shareholders iplex is .worth a minimal amount,if anything.. I was roundly ridiculed when I posted the rights for ROP would yield no more than 25 M- it was 11M- E.O.S.
IPLEX is worth BILLIONS. It is approved by the FDA for short stature and will be available to sell [drug] in 2018 without any royalty or reparations. Those are the facts. Merck has the connection to manufacture [purchased Colorado facility] and also have used in combination therapy which MDA called breakthrough.
Well, if the Increlex sales from a year ago are replicated there is likely between $200 million and $250 million in sales plus inflation. So, maybe by 2017 we get a 20% bump above their sales a couple of year ago before they canned the product. That would, in fact, represent around $2 billion in valuation.
Ok let's forget about Terry for a moment and actually talk about the topic...what's the chances of insm fetching a buyout instead of partnering - who would it be - and what price? Seems companies getting a bid for their company who are turning them down have some kind of connection with iPlex. Like Shire and AstraZeneca
Maybe Novartis (which would ditch Tobi eventually) then they would own that NTM market for quite awhile. Pure speculation but the changes in early April had an interesting twist with Drayton Wise being added:
Drayton Wise has joined as Senior Director of Commercial Operations reporting to Matthew Pauls, Chief Commercial Officer. He will focus on the design and build-out of key parts of the Company's commercial infrastructure. Previously, Mr. Wise worked at Novartis, where he led the U.S. sales launch of the TOBI Podhaler, Novartis' leading product for the treatment of CF.